Effects of aminoguanidine on adhesion molecule expression of human endothelial cells

被引:11
作者
Menzel, EJ
Neumuller, J
Sengoelge, G
Reihsner, R
机构
[1] UNIV VIENNA,DEPT NEPHROL,A-1090 VIENNA,AUSTRIA
[2] LUDWIG BOLTZMANN INST RHEUMATOL & BALNEOL,VIENNA,AUSTRIA
[3] LUDWIG BOLTZMANN INST EXPT PLAST SURG,VIENNA,AUSTRIA
[4] UNIV TECHNOL,INST STRENGTH MAT,VIENNA,AUSTRIA
关键词
adhesion molecules; human endothelial cells; nonenzymatic glycation; advanced glycation end products; aminoguanidine;
D O I
10.1159/000139520
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The effect of aminoguanidine (AG) on the expression of adhesion molecules on nonactivated human umbilical vein endothelial cells (HUVEC) was investigated in vitro, Nonactivated HUVEC cultivated on long-term glycated fibronectin (FN) as compared to native FN showed a significant upregulation of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule I (VCAM-1) and CD31 which could be further promoted by long-term glycated bovine serum albumin. AG, at a concentration of 0.01 mol/l, caused an upregulation of ICAM-1 of 48 +/- 17.4% in HUVEC cultivated on gelatin. In contrast, VCAM-1 and E-selectin remained unaffected, At this concentration, formation of advanced glycation end products (AGE) was inhibited by 57%, as determined immunologically, and by 50%, as verified by AGE-specific fluorescence. A hypothesis concerning the upregulation of ICAM-1 by AG as compared to VCAM-1 is proposed relating to its relative redox insensitivity. Our results demonstrate that the beneficial effect of AG in reducing the risk of accelerated development of atherosclerosis in diabetic patients by inhibiting formation of AGE on matrix proteins such as FN might be hampered by its tendency to upregulate ICAM-1 on endothelial cells.
引用
收藏
页码:126 / 135
页数:10
相关论文
共 36 条
[1]  
Bannai C, 1992, Diabetes Res, V20, P87
[2]  
Brownlee M, 1989, Prog Clin Biol Res, V304, P235
[3]   AMINOGUANIDINE PREVENTS DIABETES-INDUCED ARTERIAL-WALL PROTEIN CROSS-LINKING [J].
BROWNLEE, M ;
VLASSARA, H ;
KOONEY, A ;
ULRICH, P ;
CERAMI, A .
SCIENCE, 1986, 232 (4758) :1629-1632
[4]  
BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315
[5]   LIPID ADVANCED GLYCOSYLATION - PATHWAY FOR LIPID OXIDATION IN-VIVO [J].
BUCALA, R ;
MAKITA, Z ;
KOSCHINSKY, T ;
CERAMI, A ;
VLASSARA, H .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (14) :6434-6438
[6]   MODIFICATION OF LOW-DENSITY-LIPOPROTEIN BY ADVANCED GLYCATION END-PRODUCTS CONTRIBUTES TO THE DYSLIPIDEMIA OF DIABETES AND RENAL-INSUFFICIENCY [J].
BUCALA, R ;
MAKITA, Z ;
VEGA, G ;
GRUNDY, S ;
KOSCHINSKY, T ;
CERAMI, A ;
VLASSARA, H .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (20) :9441-9445
[7]   THE EFFECT OF AMINOGUANIDINE AND TOLRESTAT ON GLUCOSE TOXICITY IN BOVINE RETINAL CAPILLARY PERICYTES [J].
CHIBBER, R ;
MOLINATTI, PA ;
WONG, JSK ;
MIRLEES, D ;
KOHNER, EM .
DIABETES, 1994, 43 (06) :758-763
[8]   AMINOGUANIDINE, A NOVEL INHIBITOR OF NITRIC-OXIDE FORMATION, PREVENTS DIABETIC VASCULAR DYSFUNCTION [J].
CORBETT, JA ;
TILTON, RG ;
CHANG, K ;
HASAN, KS ;
IDO, Y ;
WANG, JL ;
SWEETLAND, MA ;
LANCASTER, JR ;
WILLIAMSON, JR ;
MCDANIEL, ML .
DIABETES, 1992, 41 (04) :552-556
[9]   ENDOTHELIAL EXPRESSION OF A MONONUCLEAR LEUKOCYTE ADHESION MOLECULE DURING ATHEROGENESIS [J].
CYBULSKY, MI ;
GIMBRONE, MA .
SCIENCE, 1991, 251 (4995) :788-791
[10]   MECHANISTIC STUDIES OF ADVANCED GLYCOSYLATION END-PRODUCT INHIBITION BY AMINOGUANIDINE [J].
EDELSTEIN, D ;
BROWNLEE, M .
DIABETES, 1992, 41 (01) :26-29